Connect Biopharma Holdings Limited Non-GAAP EPS of -$0.27 misses by $0.04, revenue of $2.77M beats by $1.9M
Connect Biopharma (CNTB) Q2 update: Non-GAAP EPS miss, revenue surge to $2.77M, R&D-driven loss and 1+ year cash runway.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Connect Biopharma (CNTB) Q2 update: Non-GAAP EPS miss, revenue surge to $2.77M, R&D-driven loss and 1+ year cash runway.
Connect Biopharma Holdings Limited Non-GAAP EPS of -$0.27 misses by $0.04, revenue of $2.77M beats by $1.9M | Seeking Alpha
Connect Biopharma Holdings Limited
press release
(
CNTB
): Q2 non-GAAP EPS of -$0.27
misses by $0.04
.
License and collaboration revenues of $2.77M (+5440.0% Y/Y) beat
 by $1.9M
.
Net loss for the quarter was $17.28M, driven by $16.27M in R&D expenses as the Rademikibart Phase 2 asthma and COPD studies completed enrollment.
Cash, cash equivalents, and short-term investments totaled $31.49M as of June 30, 2026, providing an expected cash runway of at least one year.
More on Connect Biopharma Holdings Limited
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
Historical earnings data for Connect Biopharma Holdings Limited
Financial information for Connect Biopharma Holdings Limited
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Mandatum Oyj Non-GAAP EPS of â¬0.13, revenue of â¬22.4M
Mandatum Oyj Q2 results: non-GAAP EPS â¬0.13, revenue â¬22.4M flat Y/Y, profit before taxes jumps to â¬79.1M on net finance gainsâread now.
Paragon Technologies GAAP EPS Turns Positive at $0.05, Revenue Beats at $33.3M
Paragon Technologies reports a strong quarter with GAAP EPS of $0.05 and revenue of $33.3 million, beating expectations. Improved gross margins and cost controls drive profitability, with optimistic guidance ahead.
TTEC Secures $21M IRS Contact Center Contract, Bolstering Government Services Growth
TTEC wins a $21 million IRS contact center contract, strengthening its government services segment. This analysis covers the deal's significance, industry trends, and potential impact on the stock, highlighting TTEC's competitive position in the public sector outsourcing market.
Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook
Karyopharm (KPTI) Q2 results: GAAP EPS -$2.32 miss, revenue $33.43M beats (-11.9% Y/Y), cash $65.4M.